Treatment
159
41
44
60
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Research Maturity
60 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.3%
2 terminated out of 159 trials
96.8%
+10.2% vs benchmark
12%
19 trials in Phase 3/4
13%
8 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 60 completed trials
Clinical Trials (159)
Effect of Melatonin Administration on Systemic Lupus Erythematosus Patients
Treatment of Mandibular Overjet in Children With Maxillary Retrognathism
Prevention of Relapse Through Cognitive Cycling in Patients With Alcohol Use Disorder Following Alcohol Withdrawal
Multidimensional Sleep Health Intervention to Optimize Concussion Recovery
A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal
Surgical Approach to Uterine Septum
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
Modulating Exercise Dosage to Improve Concussion Recovery
The Role of Platelet-rich Plasma Local Injection as Treatment in Improvement of Pilonidal Sinus Surgery Outcomes
Intrastromal Injection of Fluconazole in Treatment of Fungal Keratitis
Facilitators and Barriers to Eptinezumab Administration in Thailand
A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor
Brief Acceptance and Commitment Therapy for HIV-infected At-risk Drinkers
Treatment Response in Patients With Medication-Overuse Headache
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
A Trial of Chinese Traditional Medicine Combining With Intradermal Acupuncture for Treating Precocious Puberty
A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Study of The Effects of Mandibular Advancement Aligners in Treating Children With Class II Division 1 Malocclusion
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)